Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07128316 · ClinicalTrials.gov registry record · NA

LASIK Using Contoura With Phorcides vs. iDesign

A NA study of Myopia and Astigmatism, sponsored by 59th Medical Wing.

Active
Registry status
NA
Development phase
63
Enrollment target
1
Study location

NCT07128316 is a NA study of Myopia and Astigmatism that is active but no longer recruiting, run by 59th Medical Wing. The registered enrollment target is 63 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07128316, a NA study of Myopia and Astigmatism, is active but no longer recruiting, sponsored by 59th Medical Wing.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
63 participants
Enrollment target
1
Study location

Study Summary

Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

Conditions Studied

Interventions

  • DEVICE Contoura Topolyzer with Phorcides
  • DEVICE iDesign

Study Locations (1)

Texas

  • Joint Warfighter Refractive Surgery Center at WHASC - San Antonio

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2023-09-11
Est. Completion 2025-12-15
Phase NA

Sponsor

59th Medical Wing

20 total trials

What the Registry Record Tells You About NCT07128316

The ClinicalTrials.gov registry entry for NCT07128316 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The listed sponsor is 59th Medical Wing, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Contoura Topolyzer with Phorcides is the first listed.

NCT07128316 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07128316 about?

NCT07128316 is a clinical study titled "LASIK Using Contoura With Phorcides vs. iDesign". Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

What is the current status of trial NCT07128316?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 63 participants. The study started on 2023-09-11. Estimated completion is 2025-12-15.

What conditions does trial NCT07128316 study?

This clinical trial studies the following conditions: Myopia, Astigmatism.

What interventions are being tested in trial NCT07128316?

The interventions under investigation include: Contoura Topolyzer with Phorcides (DEVICE), iDesign (DEVICE).

Who is sponsoring clinical trial NCT07128316?

This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07128316 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.